Erythema multiforme after terbinafine intake

Mikologia Lekarska

Volumn 13, Issue 2, 2006, Pages 157-159

  Sidor, Monika I ^a   Reich, Adam ^b   Schwartz, Robert A ^a   Szepietowski, Jacek C ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Adverse drug reactions; Erythema multiforme; Fungal disease; Terbinafine

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; HYDROCORTISONE; TERBINAFINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; ERYTHEMA MULTIFORME; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE TEST; LABORATORY TEST; SKIN EXAMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION;

ARTHRODERMATACEAE;

EID: 33744919067     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wolverton S.E.: Comprehensive dermatologic drug therapy. W.B. Saunders Co, Philadelphia, 2001, 55-62.
2. Evens E.G., Sigurgeirsson B.: Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. Br. Med. J., 1999, 318, 1031-1035.
3. Carstens J., Wendelboe P.: Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm. Venereol., 1994, 74, 391-392.
4. Goeteyn V., Naeyaert J.M., Lambert J.: Is systemic autoimmune disease a risk factor for terbinafine induced erythema multiforme? Br. J. Dermatol., 2002, 142, 578-579.
5. Gupta A.K., Lynde C.W., Lauzon G.J., Mehlmauer M.A., Braddock S.W., Miller C.A., Del Rosso J.Q., Shear N.H.: Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br. J. Dermatol., 1998, 138, 529-532.
6. Todd P., Halpern S., Munro D.D.: Oral terbinafine and erythema multiforme. Clin. Exp. Dermatol., 1995, 20, 247-248.
7. McGregor J.M., Rustin M.H.: Terbinafine and erythema multiforme. Br. J. Dermatol., 1994, 131, 578-588.
8. Murphy M., Barnes L.: Terbinafine-induced lupus erythematosus. Br. J. Dermatol., 1998, 138, 708-709.
9. Holmes S., Kemmett D.: Exacerbation of systemic lupus erythematosus induced by terbinafine. Br. J. Dermatol., 1998, 139, 1133.
10. O'Sullivan D.P., Needman C.A., Banges A.: Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br. J. Clin. Pharmacol., 1996, 42, 559-565.
11. Castellsague J., Garcia-Rodriguez L.-A., Duque A., Perez S.: Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatology, 2002, 2, 14.
12. Roujeau J.C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., Aquier A., Bastuji-Garin S., Correia O., Locati F., Mockenhaupt M., Paoletti C., Shapiro S., Shear N., Schöpf E., Kaufman D.W.: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New Engl. J. Med., 1995, 333, 1600-1607.
13. Dalle S., Skowron F., Ronger-Savle S.: Erythema multiforme induced by fluconazole. Dermatology, 2005, 211, 169.
14. Weston W.L.: Herpes-associated erythema multiforme. J. Invest. Dermatol., 2005, 124, XV-XVI.
15. Schalock P.C., Brennick J.B., Dinulos J.G.: Mycoplasma pneumoniae infection associated with bullous erythema multiforme. J. Am. Acad. Dermatol., 2005, 52, 705-706.
16. th ed. Mosby Inc, Philadelphia, 2004, 627-628.
17. Dmochowski M., Schwartz R.A.: Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. [in:] Clinical dermatology. ed. D.J. Demis. Lippincott Williams & Wilkins, Philadelphia, 1999, Unit 7-3, 1-20.
18. Schwartz R.A., Dmochowski M.: The erythema multiforme spectrum: pathogenesis, pathology and links with the pemphigus spectrum. Post. Dermatol. Alergol., 1998, 15, 7-23.
19. Stampien T.M., Schwartz R.A.: Erythema multiforme. Am. Fam. Phys., 1992, 46, 1171-1176.
20. Geraminejad P., Walling H.W., Voigt M.D.: Severe erythema multiforme responding to interferon alfa. J. Am. Acad. Dermatol., 2006, 54, 518-521.
21. Faye O., Roujeau J.C.: Treatment of epidermal necrolysis with high dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs, 2005, 65, 2085-2090.